Interleukin-15 enhances cytokine induced killer (CIK) cytotoxic potential against epithelial cancer cell lines via an innate pathway

Human Immunology

Volumn 77, Issue 12, 2016, Pages 1239-1247

  Iudicone, Paola ^a   Fioravanti, Daniela ^a   Cicchetti, Elisabetta ^d   Zizzari, Ilaria Grazia ^b   Pandolfi, Annino ^a   Scocchera, Rita ^a   Fazzina, Raffaella ^c   Pierelli, Luca ^a,b  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c InScientiaFides Foundation   (San Marino)

^d BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Cytokine Induced Killer; Immunotherapy; Interleukin 15; Interleukin 2

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; T LYMPHOCYTE RECEPTOR; KLRK1 PROTEIN, HUMAN; NATURAL KILLER CELL LECTIN LIKE RECEPTOR SUBFAMILY K;

ADOPTIVE IMMUNOTHERAPY; ARTICLE; CANCER IMMUNOTHERAPY; CELL CULTURE; CELL EXPANSION; CELL PROLIFERATION; CELL SURFACE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOTOXICITY; EPITHELIAL CANCER CELL LINE; EX VIVO STUDY; FEMALE; HELA CELL LINE; HL 60 CELL LINE; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; K562 CELL LINE; MCF 7 CELL LINE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; CARCINOMA; EPITHELIUM CELL; HL-60 CELL LINE; IMMUNOLOGY; K-562 CELL LINE; MCF-7 CELL LINE; METABOLISM; PHYSIOLOGY; TRANSPLANTATION;

CARCINOMA; CELL PROLIFERATION; CYTOKINE-INDUCED KILLER CELLS; CYTOTOXICITY, IMMUNOLOGIC; EPITHELIAL CELLS; HELA CELLS; HL-60 CELLS; HUMANS; IMMUNITY, INNATE; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; INTERLEUKIN-2; K562 CELLS; MCF-7 CELLS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K;

EID: 85006274856     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.09.003     Document Type: Article

References (42)

1. [1] Olioso, P., Giancola, R., Di Riti, M., Contento, A., Accorsi, P., Iacone, A., Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical study. Hematol. Oncol. 27:3 (2009), 107–159.
2. [2] Linn, Y.C., Hui, K.M., Cytokine-Induced NK-like T cells: from bench to bedside. J. Biomed. Biotechnol. 435745 (2010), 1–8 doi 1135/2010/435745.
3. [3] Wang, Y., Bo, J., Dai, H., Lu, X., Lv, H., Yang, B., et al. CIK cells from recurrent or refractory AML patients can be efficiently expanded in vitro and used for reduction of leukemic blasts in vivo. Exp. Hematol. 41 (2013), 241–252.
4. [4] Schmeel, F.C., Schmeel, L.C., Gast, S.M., Schmidt-Wolf, I.G.H., Adoptive immunotherapy strategies with Cytikone-Induced Killer (CIK) cells in the treatment of hematological malignancies. Int. J. Mol. Sci. 15 (2014), 14632–14648.
5. [5] Introna, M., Borleri, G., Conti, E., Franceschetti, M., Barbui, A.M., Broady, R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 92:07 (2007), 952–959.
6. [6] Linn, Y.C., Niam, M., Chu, S., Choong, A., Yong, H.X., Heng, K.K., et al. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant. 47 (2012), 957–966.
7. [7] Benjamin, J., Laport, G., Tate, K., Galve, L., Arai, S., Lowsky, R., et al. Early infusion of donor derived CIK cells as consolidative immunotherapy following non myeloablative allogeneic transplantation: safety and feasibility. Blood 122:21 (2013), 899–903.
8. [8] Schmidt-Wolf, I.G., Lefternova, P., Mehta, B.A., Fernandez, L.P., Huhn, D., Blume, K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine induced killer cells. Exp. Hematol. 21 (1993), 1673–1679.
9. [9] Linn, Y.C., Lau, S.K.J., Liu, B.H., Ng, L.H., Yong, H.X., Hui, K.M., Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cells. Immunology 126 (2008), 423–435.
10. [10] Franceschetti, M., Pievani, A., Borleri, G., Vago, L., Fleischhauer, K., Golay, J., et al. Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Exp. Hematol. 37 (2009), 616–628.
11. [11] Pievani, A., Borleri, G., Pende, D., Moretta, L., Rambaldi, A., Golay, J., et al. Dual-functional capability of CD3+CD56+ CIK cells, a T cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 118 (2011), 3301–3310.
12. [12] Pende, D., Rivera, P., Marcenaro, S., Chien-Chung, C., Biassoni, R., Conte, R., et al. Major Histocompatibility Complex Class I-related Chain A and UL16-Binding protein expression on tumor cell lines of different histotype: analysis of tumor susceptibility to NKG2D-dependent Natural Killer cell cytotoxicity. Cancer Res. 62 (2002), 61078–66186.
13. [13] Sangiolo, D., Martinuzzi, E., Todorovic, M., Vitaggio, K., Vallario, A., Jordanev, N., et al. Alloreactivity and anti-tumor activity segregate within two distinct subsets of cytokine-induced killer (CIK) cells: implication for their infusion across major HLA barriers. Int. Immunol. 20:7 (2008), 841–848.
14. [14] Sangiolo, D., Cytokine Induced Killer Cells as promising Immunotherapy for solid tumors. J. Cancer 2 (2011), 363–368.
15. [15] Todorovic, M., Mesiano, G., Gammaitoni, L., Leuci, V., Giraudo, L., Cammarata, C., et al. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barrier. J. Immunother. 35:7 (2012), 579–586.
16. [16] Zool, B., Letherova, P., Ebert, O., Huhn, D., Von Ruecker, A., Schmidt-Wolf, I.G., Modulation of cell surface markers on NK-like T lymphocytes by using IL-2, IL-7 or IL-12 in vitro stimulation. Cytokine 12 (2000), 1385–1390.
17. [17] Helms, M.W., Prescher, J.A., Cao, Y.A., Schaffert, S., Contag, C.H., IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy. Cancer Immunol. Immunother. 59 (2010), 1325–1334.
18. [18] Jingting, J., Changping, W., Binfeng, L., Cytokine-induced killer cells promote antitumor immunity. J. Trans. Med. 11 (2013), 83–92.
19. [19] Wang, Y., Xu, Z., Zhou, F., Sun, Y., Chen, J., Li, L., et al. The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp. Hematol. Oncol., 10(4), 2015, 32, 10.1186/s40164-015-0027-9.
20. [20] Rettinger, E., Kuci, S., Naumann, I., Becker, P., Kreyenberg, H., Anzaghe, M., et al. The cytotoxic potential of Interleukin-15-stimulated cytokine-induced killer against leukemia cells. Cytotherapy 14 (2012), 91–103.
21. [21] Rettinger, E., Meyer, V., Kreyenberg, H., Volk, A., Kupi, S., Willasch, A., et al. Cytotoxic capacity of IL-15-stimulated cytokine-induced killer cells against human acute myeloid leukemia and rhabdomyosarcoma in humanized preclinical mouse models. Front. Oncol. 2 (2012), 1–10.
22. [22] Peng, Z., Liang, W., Li, Z., Xu, Y., Chen LInterleukin-15 transferred cytokine-induced killer cells elevated anti-tumor activity in a gastric tumor-bearing nude mice model. Cell Biol. Int., 2015, 10.1002/cbin.10553.
23. [23] Waldmann, T., The contrasting role of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy of rheumatological diseases. Arthritis Res. 4:3 (2002), S161–S167.
24. [24] Rutella, S., Iudicone, P., Bonanno, G., Fioravanti, D., Procoli, A., Lavorino, C., et al. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14:7 (2012), 841–850.
25. [25] Cholujova, D., Jakubikova, J., Kubes, M., Arendacka, B., Sapak, M., Ihnatko, R., et al. Comparative study of four florescent probes for evaluation of natural killer cell cytotoxicity assays. Immunobiology 213 (2008), 629–640.
26. [26] Tao, Q., Chen, T., Tao, L., Wang, H., Pan, Y., Xiong, S., et al. IL-15 improves the cytotoxicity of cytokine-induced killer cells against leukemia cells by upregulating CD3+CD8+ cells and down-regulating regulatory T cells as well as IL35. J. Immunother. 36:9 (2013), 462–467.
27. [27] Pittari, G., Filippini, P., Gentilcore, G., Grivel, J.C., Rutella, S., Revving up natural killer cells and cytokine-induced killer cells against hematological malignancies. Front. Immunol., 2015, 230, 10.3389/Immun 201500230.
28. [28] Hontscha, C., Borck, Y., Zhou, H., Messner, D., Schimdt-Wolf, I.G.H., Clinical trials on CIK cells: first report of the International Registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 137:2 (2011), 305–310.
29. [29] Schmeel, L.C., Schmeel, F.C., Coch, C., Schmidt-Wolf, I.G.H., Cytokine-induced killer (CIK) cells in cancer immunotherapy: report of the International registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 141:5 (2015), 839–849.
30. [30] Wei, C., Wang, W., Pang, W., Meng, M., Jiang, L., Xue, S., et al. The CIK cells stimulated with combination of IL2 and IL15 provide an improved cytotoxic capacity against human lung adenocarcinoma. Tumour Biol. 35:3 (2014), 1997–2007.
31. [31] Groh, V., Rhinehart, R., Secrist, H., Bauer, S., Grabstein, K.H., Spies, T., Broad tumor-associated expression and recognition by tumour derived gamma-delta T cells of MICA and MICB. Proc. Natl. Acad. Sci. 96:12 (1999), 6879–6884.
32. [32] Gammaitoni, L., Giraudo, L., Leuci, V., Todorovic, M., Mesiano, G., Picciotto, F., et al. Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features. Clin. Cancer Res. 19:16 (2013), 4347–4358.
33. [33] Chen, Y., Lin, W.S., Zhu, W.F., Lin, J., Zhou, Z.F., Huang, C.Z., et al. Tumor MICA status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer. Immunol. Res. 64:1 (2016), 251–259, 10.1007/s12026-015-8743-0.
34. [34] Cai, C., Chen, W., Miao, D., Cheng, L., Yang, G., Zhang, L., et al. Toll-like receptor 4 is required for the cytotoxicity of cytokine-induced killer cells. Acta Haematol. 132:1 (2014), 5–9.
35. [35] Pfirrmann, V., Oelsner, S., Rettinger, E., Huenecke, S., Bonig, H., Merker, M., et al. Cytomegalovirus-specific cytokine-induced killer cells: concurrent targeting of leukemia and cytomegalovirus. Cytotherapy, 17, 2015, 1139-115.
36. [36] Wang, X., Yu, W., Li, H., Yu, J., Zhang, X., Ren, X., et al. Can the dual functional capability of CIK cells be used to improve antitumor effects?. Cell. Immunol. 287 (2014), 18–22.
37. [37] Wang, H., Liu, A., Bo, W., Feng, X., Hu, Y., Tian, L., et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma patients after curative resection, a systemic review and meta-analysis. Dig. Liver Dis., 2016, 10.1016/j.dld.2016.07.010.
38. [38] Rettinger, E., Bonig, H., Wehmer, S., Lucchini, G., Willasch, A., Jarisch, A., et al. Feasibility of IL-15-activated cytokine-induced killer cell infusions after haploidentical stem cell transplantation. Bone Marrow Trasplant. 48 (2013), 1141–1143.
39. [39] Gammaitoni, L., Giraudo, L., Leuci, V., Mesiano, G., Cangemi, M., Zaccagna, A., et al. Cytokine Induced Killer cells effectively kill chemo-resistant melanoma cancer stem cells. J. Transl. Med., 13(Suppl 1), 2015, O1.
40. [40] Rong, X.X., Wei, F., Lin, X.L., Qin, Y.J., Chen, L., Wang, H.Y., et al. Recognition and killing of cancer stem-like cell population in hepatocellular carcinoma cells by cytokine-induced killer cells via NKG2D-ligands recognition. Oncoimmunology, 3, 2015, e1086060.
41. [41] Wei, F., Rong, X.X., Xie, R.Y., Jia, L.T., Wang, H.Y., Qin, Y.J., et al. Cytokine-induced killer cells efficiently kill stem-like cancer cells of nasopharyngeal carcinoma via the NKG2D-ligands recognition. Oncotarget 6:33 (2015), 35023–35039.
42. [42] Sangiolo, D., Mesiano, G., Gammaitoni, L., Leuci, V., Todorovic, M., Giraudo, L., et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas. Caner Res. 74:1 (2013), 119–129.